|0.7094||+0.0184||+2.66%||Vol 292.94K||1Y Perf 7.95%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||0.00 0.08%|
|Target Price||5.50||Analyst Rating||Strong Buy 1.33|
|Potential %||675.30||Finscreener Ranking||★★★ 49.34|
|Insiders Trans % 3/6/12 mo.||-/-100/67||Value Ranking||★+ 42.93|
|Insiders Value % 3/6/12 mo.||-/-100/100||Growth Ranking||★+ 42.14|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/99||Income Ranking||— -|
|Price Range Ratio 52W %||15.20||Earnings Rating||Strong Sell|
|Market Cap||64.15M||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Q04 2022||-0.01||-0.19||-1 800.00|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.14|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||278.06K|
|Avg. Monthly Volume||275.06K|
|Avg. Quarterly Volume||439.02K|
Cidara Therapeutics Inc. (NASDAQ: CDTX) stock closed at 0.7094 per share at the end of the most recent trading day (a 2.66% change compared to the prior day closing price) with a volume of 292.94K shares and market capitalization of 64.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Cidara Therapeutics Inc. CEO is Jeffrey Stein.
The one-year performance of Cidara Therapeutics Inc. stock is 7.95%, while year-to-date (YTD) performance is -6.2%. CDTX stock has a five-year performance of -80.51%. Its 52-week range is between 0.4601 and 2.1, which gives CDTX stock a 52-week price range ratio of 15.20%
Cidara Therapeutics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 6.50, a price-to-sale (PS) ratio of 1.25, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -60.28%, a ROC of -418.48% and a ROE of -821.79%. The company’s profit margin is -30.37%, its EBITDA margin is -54.20%, and its revenue ttm is $54.07 Million , which makes it $0.75 revenue per share.
Of the last four earnings reports from Cidara Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Cidara Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cidara Therapeutics Inc. is Strong Buy (1.33), with a target price of $5.5, which is +675.30% compared to the current price. The earnings rating for Cidara Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cidara Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cidara Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.60, ATR14 : 0.06, CCI20 : -100.74, Chaikin Money Flow : -0.10, MACD : -0.04, Money Flow Index : 44.11, ROC : -7.87, RSI : 36.85, STOCH (14,3) : 47.13, STOCH RSI : 1.00, UO : 31.75, Williams %R : -52.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cidara Therapeutics Inc. in the last 12-months were: Jeffrey Stein (Buy at a value of $51 855), Leslie Tari (Sold 19 376 shares of value $25 747 ), Preetam Shah (Sold 6 648 shares of value $10 171 ), Shah Preetam (Sold 6 648 shares of value $10 171 ), Shane M. Ward (Sold 8 658 shares of value $13 247 ), Tari Leslie (Buy at a value of $9 700), Tari Leslie (Sold 37 845 shares of value $43 292 ), Taylor Sandison (Sold 25 996 shares of value $28 874 )
Mon, 07 Aug 2023 16:15 GMT Cidara Therapeutics (CDTX) Gets a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Fri, 21 Jul 2023 12:40 GMT Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Cytokinetics (CYTK)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.